Biontech SE
A German biotechnology company that builds medicines from messenger RNA (mRNA), best known for the COVID-19 vaccine it developed with Pfizer. Its scientists in Mainz also focus on personalized cancer therapies, tailoring treatments to each patient's tumor. It was founded in 2008 by immunologists Uğur Şahin and Özlem Türeci, a married couple who met in a hospital lab, and the name blends "bio" with "NT" for "New Technologies."
American Depositary Share
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Ugur Sahin | 13G/APassive | 15.8% | 40.08M | May 15, 2026 |
| Medine GmbH | 13G/APassive | 15.5% | 39.22M | May 15, 2026 |
| ATHOS KG | 13G/APassive | 40.2% | 101.70M | May 14, 2026 |
| AT Impf GmbH | 13G/APassive | 40.2% | 101.70M | May 14, 2026 |
| Thomas Maier | 13G/APassive | 40.2% | 101.70M | May 14, 2026 |
| Prof. Ugur Sahin, M.D. | 13G/APassive | 17.6% | 42.18M | May 13, 2025 |
| Medine GmbH | 13G/APassive | 16.7% | 40.13M | May 13, 2025 |